← brief for 2026-09-12 · Slowing decline

¹⁷⁷Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer With Complex Renal Conditions: A Case Series.

Paper C Peer reviewed Observational

Key takeaways

Doctors treated men with advanced prostate cancer using a radioactive drug, Lu-177 PSMA, that the kidneys clear from the body. These men also had kidney problems, so they are usually left out of trials and there is little safety information for them. This report describes what happened to the small group the team treated, including how their kidneys held up. It is a case series with no comparison group and no reported patient count in the abstract, so it shows a link at best, not proof of cause.

Who did this work

Usmani S (Department of Radiology and Nuclear Medicine.) · Al Balushi A (Department of Radiology and Nuclear Medicine.) · Al Saadi S (Department of Medical Oncology, Sultan Qaboos Comprehensive Cancer Care and Research Centre (SQCCCRC), University Medical City, Muscat, Oman.) · Jain A (Department of Radiology and Nuclear Medicine.) · Al Harthy M (Department of Medical Oncology, Sultan Qaboos Comprehensive Cancer Care and Research Centre (SQCCCRC), University Medical City, Muscat, Oman.) · Ismaila A (Department of Radiology and Nuclear Medicine.) · Al Busaidi A (Department of Radiology and Nuclear Medicine.) · Al Riyami K (Department of Radiology and Nuclear Medicine.)

Source

Paper · Europe PMC, CKD · 2026-09-09
https://doi.org/10.1097/rlu.0000000000006689